Impact Therapeutics KOL Event at ASCO 2022

June 5, 2022

The Impact Therapeutics Team is excited to host a KOL Event at ASCO on Sunday, June 5, 2022, during the 2022 ASCO Annual Meeting. 

 Dr. Tim Yap from MD Anderson Cancer Center will give a keynote speech on clinical development of DDR agents.  Impact’s senior management and PI’s will discuss the company’s pipeline and clinical developments.  

For more information, please reach out to Michael at

General Agenda
6pm CT - Registration

6:30pm - 9:00pm CT - Event

RSVP for Event / Log Back in Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

Impact Therapeutics Inc
The JV is cur­rent­ly con­duct­ing a Phase II piv­o­tal study and a Phase III study of Se­na­parib in ovarian can­cer third-line treat­ment and first-line main­te­nance treat­ment in Chi­na. Out­side Chi­na, IM­PACT alone is con­duct­ing a Phase I/II study of Se­na­parib and te­mo­zolo­mide com­bi­na­tion ther­a­py in solid tu­mors and small cell lung can­cer treat­ment, as well as a Phase II study of Se­na­parib monother­a­py in pros­tate can­cer main­te­nance treat­ment. [more in­for­ma­tion]